{"nctId":"NCT02203838","briefTitle":"Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia","startDateStruct":{"date":"2014-06"},"conditions":["Schizophrenia"],"count":500,"armGroups":[{"label":"RBP-7000 - 120-mg dose","type":"EXPERIMENTAL","interventionNames":["Drug: RBP-7000"]}],"interventions":[{"name":"RBP-7000","otherNames":["Risperidone","Long-acting Risperidone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\"De Novo\" Patients\n\n* Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual, Edition 4, text revision (DSM-IV-TR) criteria\n* Total PANSS score \\<=70 at the time of screening (Visit 1)\n* Otherwise healthy on the basis of physical examinatIon\n* Provided written informed consent\n\n\"Roll-over Patients\n\n* Provided written consent to participate in this study\n* Be considered eligible to enroll based on End of Study (EOS) (Day 57 of Study RB-US-09-0010) assessments and the medical judgment of the investigator\n\nExclusion Criteria:\n\n\"De Novo\" Patients\n\n* Patients taking daily oral risperidone at a dose plus/minus 6 mg/day\n* Patients taking any risperidone or 9-hydroxyrisperidone long-acting injectable formulation within 120 days of study screening (Visit 1)\n* Patients who have received a long-acting injectable antipsychotic within 120 days of screening (Visit 1)\n* Patients with evidence or history (in the past six months prior to screening) of a significant hepatic disorder that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug, including:\n\n  * Acute or chronic hepatitis, including but not limited to hepatitis B or C\n  * Total bilirubin greater than 1.5 times the upper limit of normal (ULN), or\n  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times ULN\n* Patients with a history of drug-induced leukopenia\n* Patients with other medical conditions including, but not limited to, history of heart attack (myocardial infarction) or brain injury (traumatic injury with loss of consciousness and/or cerebrovascular accident), and clinically significant low blood pressure or arrhythmias as interpreted by the primary investigator (PI) or medically qualified sub-investigator\n* Patients with epilepsy or other seizure disorders, Parkinson's disease or dementia\n\n\"Roll-over\" Patients\n\n* Patients requiring an inpatient treatment setting at the end of Study RB-US-09-0010\n* Patients with an unstable medical condition developed during Study RB-US-09-0010\n* Women of childbearing potential who have a positive pregnancy test at screening (Visit 1), who are pregnant or breastfeeding, seeking pregnancy, or failing to use adequate contraceptive methods during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Treatment-Emergent Adverse Events (TEAE)","description":"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.\n\nA serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With Injection Site-Related Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date.\n\nAdverse events were coded using MedDRA version 17.0. Preferred terms linked to injection site AEs are reported. Although a participant may have had 2 or more AEs, the subject is counted only once in each preferred term category. The same subject may appear in different preferred term categories.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With Markedly Abnormal Weight Gain Anytime During the Study as Compared to Baseline","description":"Participants who were found to have gain \\>=7% and \\>=10% of their baseline weight at any point during the study (including unscheduled assessments) once treatment began.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score to Days 29, 169 and End of Study","description":"The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"5.70"},{"groupId":"OG001","value":"-4.8","spread":"11.11"},{"groupId":"OG002","value":"-8.3","spread":"13.43"},{"groupId":"OG003","value":"-2.4","spread":"10.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"6.84"},{"groupId":"OG001","value":"-8.2","spread":"18.96"},{"groupId":"OG002","value":"-10.0","spread":"14.42"},{"groupId":"OG003","value":"-9.4","spread":"9.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"8.67"},{"groupId":"OG001","value":"-20.2","spread":"15.59"},{"groupId":"OG002","value":"-12.5","spread":"15.53"},{"groupId":"OG003","value":"-10.9","spread":"13.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores to End of Study","description":"PANSS subscales:\n\n* Positive scale assesses 7 items: delusions, conceptual disorganization, hallucinations, excitement, grandiosity, suspiciousness/persecution, and hostility. Scale: 7 (absent) to 49 (extreme psychopathology)\n* Negative scale assesses 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. Scale: 7 (absent) to 49 (extreme psychopathology)\n* General Psychopathology scale assesses 16 items: somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. Scale: 16 (absent) to 112 (extreme psychopathology) Negative change from baseline scores indicate improvements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.29"},{"groupId":"OG001","value":"-7.8","spread":"5.49"},{"groupId":"OG002","value":"-3.7","spread":"4.08"},{"groupId":"OG003","value":"-3.7","spread":"3.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"3.56"},{"groupId":"OG001","value":"-4.0","spread":"5.93"},{"groupId":"OG002","value":"-4.1","spread":"4.60"},{"groupId":"OG003","value":"-0.9","spread":"3.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"5.00"},{"groupId":"OG001","value":"-8.3","spread":"6.95"},{"groupId":"OG002","value":"-4.7","spread":"8.99"},{"groupId":"OG003","value":"-6.4","spread":"7.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity Scores (CGI-S) to Days 29, 169 and End of Study","description":"The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\". Negative change from baseline scores indicate improvement in the severity of illness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.35"},{"groupId":"OG001","value":"-0.3","spread":"0.82"},{"groupId":"OG002","value":"-0.2","spread":"0.80"},{"groupId":"OG003","value":"-0.1","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.48"},{"groupId":"OG001","value":"-0.3","spread":"1.32"},{"groupId":"OG002","value":"-0.3","spread":"0.59"},{"groupId":"OG003","value":"-0.4","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.66"},{"groupId":"OG001","value":"-1.0","spread":"1.10"},{"groupId":"OG002","value":"-0.5","spread":"0.64"},{"groupId":"OG003","value":"-0.3","spread":"1.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":408},"commonTop":["Injection site pain","Weight increased","Insomnia","Injection site nodule","Schizophrenia"]}}}